Table 1.

IC50 of phosphorylation (μmol/L) of IGF1R, AKT, and MAPK after ADW742 treatment alone or combined with imatinib, doxorubicin, or vincristine and IC50 of proliferation of all cell lines after ADW742, imatinib, doxorubicin, or vincristine treatment at 72 hours of incubation

DrugMoleculeCell line
A673TC-71SK-ES-1A4573
IC50 of phosphorylation (μmol/L)
    ADWp-IGF1R0.508 ± 0.120.244 ± 0.0980.184 ± 0.1540.171 ± 0.053
p-AKT1 ± 0.540.29 ± 0.060.35 ± 0.0130.81 ± 0.028
p-MAPK>5>53 ± 2.832.08 ± 0.35
p-mTOR0.51 ± 0.0230.308 ± 0.0450.24 ± 0.0180.41 ± 0.098
    ADW + imatinibp-AKT0.567 ± 0.090.176 ± 0.010.217 ± 0.080.61 ± 0.06
p-MAPK4.1 ± 0.8>53.085 ± 1.291.498 ± 0.039
p-mTOR0.17 ±0.0240.041 ± 0.00340.087 ± 0.00490.17 ± 0.068
    ADW + doxorubicinp-AKT0.55 ± 0.080.231 ± 0.0780.186 ± 0.030.68 ± 0.09
p-MAPK>54.5 ± 1.23.6 ± 2.391.385 ± 0.89
    ADW + vincristinep-AKT0.97 ± 0.890.291 ± 0.0930.23 +7- 0.0930.875 ± 0.087
p-MAPK>54.61 ± 0.523.656 ± 2.310.93 ± 0.028
IC50 of proliferation
    ADW (nmol/L)1410 ± 280670 ± 80550 ± 50640 ± 60
    Imatinib (μmol/L)18.77 ± 4.0222.00 ± 3.2018.90 ± 3.6020.12 ± 2.21
    Doxorubicin (ng/mL)276 ± 35.1782 ± 11.886 ± 8.2465.5 ± 3.06
    Vincristine (ng/mL)3.20 ± 0.353.76 ± 0.433.5 ± 0.193.7 ± 027